The Barbara Ann Karmanos Cancer Institute, headquartered in Detroit, is the largest cancer research and provider network in Michigan and has 16 treatment locations. It is one of 51 National Cancer Institute-designated comprehensive cancer treatment and research centers in the United States.

There are 123 beds in Wayne State University/Karmanos Cancer Institute.

During the past decade, Wayne State University/Karmanos Cancer Institute conducted 233 clinical trials. In the 10-year time frame, 233 clinical trials started and 193 clinical trials were completed, i.e. on average, 82.8% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 113 clinical trials were completed. i.e. 166.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wayne State University/Karmanos Cancer Institute" #1 sponsor was "National Cancer Institute (NCI)" with 198 trials, followed by "Children's Oncology Group" with 66 trials sponsored, "SWOG Cancer Research Network" with 34 trials sponsored, "Seagen Inc." with 21 trials sponsored and "Alliance for Clinical Trials in Oncology" with 21 trials sponsored. Other sponsors include 123 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wayne State University/Karmanos Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 199 trials as a collaborator, "NRG Oncology" with 34 trials as a collaborator, "Canadian Cancer Trials Group" with 11 trials as a collaborator, "Bristol-Myers Squibb" with 7 trials as a collaborator and "Cancer and Leukemia Group B" with 6 trials as a collaborator. Other collaborators include 109 different institutions and companies that were collaborators in the rest 86 trials.

According to Clinical.Site data, the most researched conditions in "Wayne State University/Karmanos Cancer Institute" are "Recurrent Ovarian Carcinoma" (15 trials), "Acute Lymphoblastic Leukemia" (12 trials), "Acute Myeloid Leukemia" (11 trials), "Recurrent Fallopian Tube Carcinoma" (11 trials) and "Recurrent Melanoma" (11 trials). Many other conditions were trialed in "Wayne State University/Karmanos Cancer Institute" in a lesser frequency.

Most popular intervention types in "Wayne State University/Karmanos Cancer Institute" are "Drug" (374 trials), "Other" (277 trials), "Biological" (129 trials), "Procedure" (107 trials) and "Radiation" (93 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (181 trials), "Quality-of-Life Assessment" (79 trials), "Questionnaire Administration" (56 trials), "Carboplatin" (45 trials) and "Pharmacological Study" (45 trials). Other intervention names were less common.

The vast majority of trials in "Wayne State University/Karmanos Cancer Institute" are 363 trials for "All" genders, 71 trials for "Female" genders and 30 trials for "Male" genders.

Currently, there are NaN active trials in "Wayne State University/Karmanos Cancer Institute". undefined are not yet recruiting, 77 are recruiting, 194 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 152 completed trials in Wayne State University/Karmanos Cancer Institute, 5 suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Wayne State University/Karmanos Cancer Institute, 67 "Phase 1" clinical trials were conducted, 220 "Phase 2" clinical trials and 180 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 10 trials that are defined as “Not Applicable".